Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine (Experimental) Clear all
Recruiting Not applicable Interventional

Personalized Addiction Treatment enHancement

NCT07778394
View directory record Official record
Conditions
Opioid Use Disorder, mHealth, Peer Support
Interventions
Vira Platform, Treatment-As-Usual
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
22 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Not applicable Interventional Results available

Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings

NCT03698669
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Treating Opioid Patients' Pain and Sadness (TOPPS), Health Education (HE)
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years to 65 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Fall River, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 13, 2026, 1:12 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Treatment Extension Study

NCT02896296
View directory record Official record
Conditions
Opioid Use Disorder, Opioid-related Disorders
Interventions
RBP-6000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
29
States / cities
Hamilton, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

NCT02479308
View directory record Official record
Conditions
Healthy
Interventions
Moxifloxacin, ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction

NCT02801357
View directory record Official record
Conditions
Substance Withdrawal Syndrome, Opiate Addiction, Opiate Dependence
Interventions
lofexidine administration in subjects seeking buprenorphine dose reduction
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 13, 2026, 1:12 PM EDT
Not yet recruiting Phase 4 Interventional

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

NCT07469501
View directory record Official record
Conditions
Opioid Use Disorder, Fentanyl
Interventions
Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Not applicable Interventional Results available

Reward-Based Recovery Outcomes Management for Opioid Use Disorder

NCT04669249
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
PROCare
Behavioral
Lead sponsor
Medical Decision Logic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 13, 2026, 1:12 PM EDT
Enrolling by invitation Phase 4 Interventional

Houston Emergency Opioid Engagement System

NCT03396276
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Suboxone, Brief counseling in the ED, Referral to outpatient treatment, Follow-up coaching
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

NCT00312195
View directory record Official record
Conditions
Chronic Non-malignant Pain
Interventions
Buprenorphine transdermal patch, Placebo to match BTDS
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
21
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT00490919
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine transdermal system, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 13, 2026, 1:12 PM EDT
Active, not recruiting Not applicable Interventional

Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care

NCT04601064
View directory record Official record
Conditions
HIV Infections, Substance Use Disorders, Mental Health Disorder, Addiction, Opioid Use, Drug Use
Interventions
Collaborative Care Model
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Not applicable Interventional Results available

Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments

NCT02586896
View directory record Official record
Conditions
Opioid Dependence
Interventions
Strengths-based Case Management (SBCM), Screening, Assessment, and Referral (SAR)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 13, 2026, 1:12 PM EDT
Not listed Phase 2 Interventional

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

NCT06434818
View directory record Official record
Conditions
Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder, Methamphetamine-dependence
Interventions
EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks, CBOT Sham
Combination Product
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 2Phase 3 Interventional

Directly Administered HIV Therapy in Methadone Clinics

NCT00279110
View directory record Official record
Conditions
HIV Infections, Heroin Dependence
Interventions
Directly administered antiretroviral therapy (DAART)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

NCT02666001
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Methadone, Buprenorphine and Norbuprenorphine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 13, 2026, 1:12 PM EDT
Withdrawn Phase 4 Interventional

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

NCT01015066
View directory record Official record
Conditions
Opiate Addiction
Interventions
Buprenorphine/naloxone, Naltrexone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 13, 2026, 1:12 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals

NCT03711318
View directory record Official record
Conditions
Heroin Dependence
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)

NCT00571961
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra (lopinavir/ritonavir), buprenorphine, Clinical evaluations/Blood draws
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 13, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals

NCT04982627
View directory record Official record
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
Interventions
BNI Chatbot, OUD Education & Treatment Resources
Behavioral
Lead sponsor
Center for Progressive Recovery, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 13, 2026, 1:12 PM EDT
Terminated Phase 3 Interventional Results available

Virginia Opioid Overdose Treatment InitiatVE

NCT03818399
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
SUBLOCADE
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 13, 2026, 1:12 PM EDT